| Description |
1 online resource (xvi, 475 pages) |
| Series |
Contemporary clinical neuroscience |
|
Contemporary clinical neuroscience.
|
| Contents |
Part I Introduction -- The Utility of Biomarkers for Huntington’s Disease -- Part II Biofluid Sources for Huntington’s Disease Biomarkers -- Cerebrospinal Fluid Biomarkers in Huntington’s Disease -- Extracellular Vesicles as Possible Sources of Huntington’s Disease Biomarkers -- Saliva as a Relevant Biofluid for Huntington’s Disease Biomarker Research -- Part III Neuroimaging Biomarkers for Huntington’s Disease -- Retinal Imaging and Functional Biomarkers of Huntington’s Disease -- Positron Emission Tomography (PET) Imaging Biomarkers in Huntington’s Disease -- Functional and Physiological MRI Measures as Early Biomarkers for Huntington’s Disease -- Part IV Multi-omics Approaches to Biomarker Discovery -- Metabolomics in Huntington’s Disease -- Proteomics in Huntington’s Disease Biomarker Discovery -- Microbiome and Metabolomic Biomarkers for Huntington’s Disease -- Part V Biochemical and Genetic Biomarkers in Huntington’s Disease -- Inflammation Biomarkers in Huntington’s Disease -- Astrocytes in Huntington’s Disease Pathology: Implications for Biomarkers -- Mitochondrial/Oxidative Stress Biomarkers in Huntington’s Disease -- TAR DNA-Binding Protein 43 as a Potential Biomarker for Huntington’s Disease -- DNA Methylation and Epigenetic Aging Biomarkers in Huntington’s Disease -- MicroRNAs as Potential Biomarkers in Huntington’s Disease -- Part VI Biomarker Considerations for Clinical Trial Design -- Considerations and Advances in Huntington’s Disease Clinical Trial Design -- Digital Measures in Huntington’s Disease -- Sex Differences in Huntington’s Disease: Considerations for Clinical Care and Research Trials |
| Summary |
Huntingtons disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important |
| Notes |
Includes index |
|
Online resource; title from PDF title page (SpringerLink, viewed October 23, 2023) |
| Subject |
Huntington's disease -- Diagnosis
|
|
Biochemical markers.
|
|
Biomarkers
|
|
Biochemical markers
|
| Form |
Electronic book
|
| Author |
Thomas, Elizabeth A
|
|
Parkin, Georgia M
|
| ISBN |
9783031328152 |
|
3031328159 |
|
